MORGANTOWN, W.Va. – Mylan pharmaceuticals has been ordered to pay $30 million by the Security and Exchange Commission for overcharges related to the sale of the EpiPen. The EpiPen is Mylan’s top revenue generator.

The government complaint says Mylan paid much lower rebates to the government because of the classification of the drug. The complaint goes onto say the drug was wrongly classified as a generic drug in October of 2014.

The SEC made the ruling following a two-year civil investigation by the U. S. Department of Justice.

“As alleged in our complaint, investors were kept in the dark about Mylan’s EpiPen misclassification and the potential loss Mylan faced as a result of the pending investigation into the misclassification,” said Antonia Chion, Associate Director in the SEC’s Division of Enforcement. “It is critical that public companies accurately disclose material business risks and timely disclose and account for loss contingencies that can materially affect their bottom line.”